In conclusion, the effectiveness and safety of Zercepac were comparable to that of reference trastuzumab in HER2-positive breast cancer when administered in the neoadjuvant setting with pertuzumab, docetaxel, and platinum. This evidence concerns the gene ERBB2 and breast cancer.